

# Cervical Cancer and COVID: A collaborative assessment of the effect of the COVID pandemic on the presentation of Cervical cancer in the North of England

Jennifer Davies<sup>1</sup>, Alice Spencer<sup>1</sup>, Sian Macdonald<sup>1</sup>, Lucy Dobson<sup>1</sup>, Emily Haydock<sup>2</sup>, Holly Burton<sup>2</sup>, Georgios Angelopoulos<sup>2</sup>, Pierre Martin-Hirsch<sup>2</sup>, Nicholas Wood<sup>2</sup>, Richard Edmondson<sup>3</sup>, Amudha Thangavelu<sup>4</sup>, Richard Hutson<sup>4</sup>, Sarika Munot<sup>4</sup>, Marina Flynn<sup>5</sup>, Katelijn Sap<sup>6</sup>, Michael Smith<sup>6</sup>, Eva Myriokefalitaki<sup>7</sup>, Brett Winter-Roach<sup>7</sup>, Bridget Decruze<sup>6</sup>, and Robert MacDonald<sup>1</sup>

<sup>1</sup>Liverpool Women's Crown Street Hospital

<sup>2</sup>Lancashire Teaching Hospitals NHS Foundation Trust

<sup>3</sup>The University of Manchester

<sup>4</sup>Leeds Teaching Hospitals NHS Trust

<sup>5</sup>Hull University Teaching Hospitals NHS Trust

<sup>6</sup>The Christie NHS Foundation Trust

<sup>7</sup>Christie Hospital

July 18, 2021

## Abstract

**Objective:** To review the effect of the COVID-19 pandemic on the presentation of Cervical cancer. **Design/ Setting:** Retrospective study involving the Regional Cancer Centres in the M62 Group. **Methods:** Data was collected for two equal time periods. All cervical cancers were included and FIGO 2018 staging was used for the data collection. P values were calculated using binomial hypothesis test for the difference in staging. Time from symptoms to diagnosis was assessed using a normal distribution test. All other calculations were performed using chi-squared test. Statistical significance was considered if p values were <0.05. **Main outcome measures:** Histology, stage at diagnosis, date of onset of symptoms, investigation and type of treatment. **Results:** A total of 406 cases of cervical cancer were reviewed; 233 from May – October 2019 (pre-COVID) and 173 between May – October 2020 (post COVID); representing a significant reduction in new cervical cancer diagnoses of 25% post COVID (p<0.001) There was a 42% increase in the delay from start of symptoms to diagnosis Post COVID. Pre COVID, 27% of patients presented with Stage 3 or 4 disease, whilst during COVID this was 38%; statistically significant (p <0.001). When we evaluated the treatments received between the two time periods, this was also statistically significant (chi-squared, p=0.0005). **Conclusions:** This study has demonstrated a statistically significant increase in the stage of cervical cancer at diagnosis and a change in treatment for cervical cancer following the onset of COVID-19. The implications of this are discussed.

## Hosted file

Cervical Cancer and COVID paper BJOG Submission.docx available at <https://authorea.com/users/426288/articles/530842-cervical-cancer-and-covid-a-collaborative-assessment-of-the-effect-of-the-covid-pandemic-on-the-presentation-of-cervical-cancer-in-the-north-of-england>